Powder: -20°C for 3 years | In solvent: -80°C for 1 year
E2730 is a selective and noncompetitive inhibitor of the gamma-aminobutyric acid (GABA) transporter 1 (GAT1) that exhibits oral availability as well as antiepileptic properties. Its inhibition of GAT1 is dependent on the prevailing GABA concentrations and specifically targets GAT1-mediated GABA uptake. Demonstrating in vivo effectiveness, E2730 has been tested at doses ranging from 5-50 mg/kg orally in various models, including the rat amygdala kindling and the mouse corneal kindling models, as well as in drug-resistant psychomotor epilepsy, fragile X syndrome at 2.5-300 mg/kg, and Dravet syndrome at dosages of 10 mg/kg and 20 mg/kg [1].
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
説明 | E2730 is a selective and noncompetitive inhibitor of the gamma-aminobutyric acid (GABA) transporter 1 (GAT1) that exhibits oral availability as well as antiepileptic properties. Its inhibition of GAT1 is dependent on the prevailing GABA concentrations and specifically targets GAT1-mediated GABA uptake. Demonstrating in vivo effectiveness, E2730 has been tested at doses ranging from 5-50 mg/kg orally in various models, including the rat amygdala kindling and the mouse corneal kindling models, as well as in drug-resistant psychomotor epilepsy, fragile X syndrome at 2.5-300 mg/kg, and Dravet syndrome at dosages of 10 mg/kg and 20 mg/kg [1]. |
分子量 | 284.23 |
分子式 | C9H8F4N2O2S |
CAS No. | 1520073-91-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
E2730 1520073-91-9 Membrane transporter/Ion channel Neuroscience GABA Receptor Inhibitor inhibitor inhibit